Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie : Declares Quarterly Dividend

09/13/2021 | 10:09am EDT

NORTH CHICAGO, Ill. - The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.30 per share.

The cash dividend is payable November 15, 2021 to stockholders of record at the close of business on October 15, 2021.

Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Contact:

Investors

Liz Shea

T: (847) 935-2211

E: liz.shea@abbvie.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ABBVIE INC.
10/21ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
MT
10/18ABBVIE : Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Ad..
AQ
10/18OYSTER POINT PHARMA : drug becomes first FDA-approved nasal spray to treat dry eyes
RE
10/15REVANCE THERAPEUTICS : U.S. FDA declines to approve Revance's frown-line treatment
RE
10/15ABBVIE : Says its Psoriatic Arthritis Drug Risankizumab Recommended by CHMP for Treatment ..
MT
10/15AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI«) for the Treatment of ..
CI
10/15AbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis
DJ
10/14PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..
DJ
10/14ABBVIE INC. : Ex-dividend day for
FA
10/12ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..
AQ
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 188 M - -
Net income 2021 12 472 M - -
Net Debt 2021 66 426 M - -
P/E ratio 2021 14,8x
Yield 2021 4,79%
Capitalization 192 B 192 B -
EV / Sales 2021 4,59x
EV / Sales 2022 4,12x
Nbr of Employees 48 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 108,50 $
Average target price 125,48 $
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.1.26%191 739
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158